Benzodiazepine Drugs Market is Estimated to Witness High Growth Owing to Increasing Incidence of Anxiety Disorders

Comments · 21 Views

Benzodiazepine drugs are a class of psychoactive compounds widely used to treat conditions such as anxiety, insomnia and more. These drugs work by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, producing a calming effect. Common benzodiazepines prescribed include alprazolam, diazepam, lorazepam and clonazepam. Benzodiazepine drugs are prescription drugs and are effective in relieving symptoms of anxiety and panic. They are also used as sedatives or hypnotics for short-term treatment of insomnia and produce muscle relaxation.

 

The global Benzodiazepine Drugs Market is estimated to be valued at US$ 3148.01 Mn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Opportunity:

Increasing incidence of anxiety disorders across the globe is expected to offer significant growth opportunities for benzodiazepine drugs market. According to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S., affecting nearly 40 million adults in the United States age 18 and older every year. Generalized anxiety disorder is one of the most prevalent psychological disorders in the U.S. The rising mental health issues are expected to fuel the demand for effective treatment options like benzodiazepine drugs for fast relief of anxiety symptoms over the forecast period. Growing acceptance of benzodiazepines for short term treatment of anxiety disorders presents potential lucrative opportunities for players in the benzodiazepine drugs market.

 

Porter’s Analysis

Threat of new entrants: The threat of new entrants is moderate as benzodiazepine drugs market requires considerable investments in R&D, clinical trials, and obtaining regulatory approvals. Bargaining power of buyers: The bargaining power of buyers is low due to standardized nature of benzodiazepine drugs with limited availability of substitutes. Bargaining power of suppliers: The bargaining power of suppliers is moderate as raw material supplies are concentrated among few players globally. Threat of new substitutes: The threat of substitutes is moderate as other classes of drugs are being explored for alternative therapies in anxiety and seizure disorders. Competitive rivalry: The competitive rivalry is high among the key global players operating in the benzodiazepine drugs market.

 

SWOT Analysis

Strength: Benzodiazepine drugs are effective and safe treatment options for several medical conditions like anxiety, insomnia, seizures etc. Extensive clinical research data available for long-term usage.

Weakness: Possibility of dependency and abuse on long-term usage. Withdrawal symptoms observed on discontinuation. Opportunities: Untapped growth opportunities in developing nations. Increasing prevalence of anxiety, panic disorders, and epilepsy presents scope for market expansion.

Threats: Stringent regulations pertaining drug approvals. Vulnerable to patent expiries of key drug formulations. Rising development of alternative non-drug treatments.

 

Key Takeaways

The Global Benzodiazepine Drugs Market Size is expected to witness high growth during the forecast period owing to rising prevalence of diseases like epilepsy, anxiety disorders worldwide.

Regionally, North America dominated the global benzodiazepine drugs market in 2020 and is expected to maintain its dominance over the forecast period. This can be attributed to growing prevalence of target diseases, surging demand for safe and effective prescription drugs, and presence of major market players in the region.

 

Key players operating in the benzodiazepine drugs market are Bioderma Laboratories, Lotus Herbals Pvt. Ltd., Natura & Co., Kao Corporation, Beiersdorf AG, Procter & Gamble Co., Unilever PLC, Moroccan Oil, L'Oreal SA, Himalaya Wellness Company, Johnson & Johnson Inc., and The Estee Lauder Companies Inc. Among them, major brands like Xanax (alprazolam) of Pfizer, Klonopin (clonazepam) of Roche, and Valium (diazepam) of Roche have wider consumer acceptance and demand globally. There is intense competition among the key manufacturers for new drug development and geographical expansion.


Get More Insights Here

https://www.trendingwebwire.com/benzodiazepine-drugs-market-size-share-growth-outlook-2023/

disclaimer
Comments